CA2703170C - Composition comprising myelin basic proteins - Google Patents

Composition comprising myelin basic proteins Download PDF

Info

Publication number
CA2703170C
CA2703170C CA2703170A CA2703170A CA2703170C CA 2703170 C CA2703170 C CA 2703170C CA 2703170 A CA2703170 A CA 2703170A CA 2703170 A CA2703170 A CA 2703170A CA 2703170 C CA2703170 C CA 2703170C
Authority
CA
Canada
Prior art keywords
mbp
peptide
composition
hla
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2703170A
Other languages
English (en)
French (fr)
Other versions
CA2703170A1 (en
Inventor
David Wraith
Heather Streeter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Worg Pharmaceuticals Zhejiang Co Ltd
Original Assignee
Apitope Technology Bristol Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0721430A external-priority patent/GB0721430D0/en
Priority claimed from GB0800962A external-priority patent/GB0800962D0/en
Application filed by Apitope Technology Bristol Ltd filed Critical Apitope Technology Bristol Ltd
Publication of CA2703170A1 publication Critical patent/CA2703170A1/en
Application granted granted Critical
Publication of CA2703170C publication Critical patent/CA2703170C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Confectionery (AREA)
CA2703170A 2007-10-31 2008-10-30 Composition comprising myelin basic proteins Active CA2703170C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0721430A GB0721430D0 (en) 2007-10-31 2007-10-31 Composition
GB0721430.7 2007-10-31
GB0800962.3 2008-01-18
GB0800962A GB0800962D0 (en) 2008-01-18 2008-01-18 Conposition
PCT/GB2008/003673 WO2009056833A2 (en) 2007-10-31 2008-10-30 Composition

Publications (2)

Publication Number Publication Date
CA2703170A1 CA2703170A1 (en) 2009-05-07
CA2703170C true CA2703170C (en) 2016-10-11

Family

ID=40591554

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2703170A Active CA2703170C (en) 2007-10-31 2008-10-30 Composition comprising myelin basic proteins

Country Status (23)

Country Link
US (3) US8623827B2 (https=)
EP (1) EP2211892B1 (https=)
JP (1) JP5361895B2 (https=)
KR (1) KR101570383B1 (https=)
CN (1) CN101848725B (https=)
AT (1) ATE518546T1 (https=)
AU (1) AU2008320657B2 (https=)
BR (1) BRPI0818302B1 (https=)
CA (1) CA2703170C (https=)
CY (1) CY1112620T1 (https=)
DK (1) DK2211892T3 (https=)
EA (1) EA017999B1 (https=)
EC (1) ECSP10010211A (https=)
HR (1) HRP20110724T1 (https=)
IL (1) IL204662A (https=)
MX (1) MX2010004698A (https=)
MY (1) MY158800A (https=)
NZ (1) NZ583924A (https=)
PL (1) PL2211892T3 (https=)
PT (1) PT2211892E (https=)
SI (1) SI2211892T1 (https=)
WO (1) WO2009056833A2 (https=)
ZA (1) ZA201001748B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1731912T1 (sl) 2000-08-21 2014-05-30 Apitope Technology (Bristol) Limited Postopek izbire peptida
AU2008320657B2 (en) 2007-10-31 2013-09-05 Worg Pharmaceuticals (Zhejiang) Co., Ltd. Composition
DK2488196T3 (en) * 2009-10-12 2016-03-14 Lifebio Lab Llc A composition for treating multiple sclerosis
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
GB201603582D0 (en) * 2016-03-01 2016-04-13 Apitope Int Nv Peptides
GB201700095D0 (en) * 2017-01-04 2017-02-22 Apitope Int Nv Composition
WO2018127828A1 (en) * 2017-01-04 2018-07-12 Apitope International Nv Therapeutic method using tolerogenic peptides
JP7419229B2 (ja) * 2017-08-14 2024-01-22 百明信康生物技術（浙江）有限公司 方法
BR112023021222A2 (pt) 2021-04-16 2024-01-16 Cour Pharmaceuticals Dev Company Inc Método de rastreamento de manutenção de tolerância imunológica

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817629A (en) * 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
SI1731912T1 (sl) 2000-08-21 2014-05-30 Apitope Technology (Bristol) Limited Postopek izbire peptida
US20040096456A1 (en) 2000-12-01 2004-05-20 Conti-Fine Bianca M Method to treat hemophilia
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
AU2008320657B2 (en) 2007-10-31 2013-09-05 Worg Pharmaceuticals (Zhejiang) Co., Ltd. Composition

Also Published As

Publication number Publication date
AU2008320657B2 (en) 2013-09-05
ATE518546T1 (de) 2011-08-15
JP5361895B2 (ja) 2013-12-04
NZ583924A (en) 2012-06-29
CN101848725A (zh) 2010-09-29
US9775880B2 (en) 2017-10-03
HK1142803A1 (en) 2010-12-17
ECSP10010211A (es) 2010-08-31
US20100286054A1 (en) 2010-11-11
KR101570383B1 (ko) 2015-11-19
PL2211892T3 (pl) 2012-01-31
EP2211892A2 (en) 2010-08-04
SI2211892T1 (sl) 2011-12-30
CN101848725B (zh) 2013-05-22
EA017999B1 (ru) 2013-04-30
IL204662A0 (en) 2010-11-30
AU2008320657A1 (en) 2009-05-07
WO2009056833A2 (en) 2009-05-07
EA201070541A1 (ru) 2010-12-30
MY158800A (en) 2016-11-15
US8623827B2 (en) 2014-01-07
CA2703170A1 (en) 2009-05-07
KR20100036391A (ko) 2010-04-07
US20140161832A1 (en) 2014-06-12
HRP20110724T1 (hr) 2011-12-31
WO2009056833A3 (en) 2009-11-26
IL204662A (en) 2013-07-31
MX2010004698A (es) 2010-05-13
BRPI0818302A2 (https=) 2018-08-21
CY1112620T1 (el) 2016-02-10
DK2211892T3 (da) 2011-10-31
JP2011500776A (ja) 2011-01-06
US9381234B2 (en) 2016-07-05
US20160263188A1 (en) 2016-09-15
EP2211892B1 (en) 2011-08-03
BRPI0818302B1 (pt) 2022-04-12
PT2211892E (pt) 2011-10-18
ZA201001748B (en) 2011-06-29

Similar Documents

Publication Publication Date Title
US9775880B2 (en) Methods of using myelin basis protein peptide compositions
US8343500B2 (en) Peptide composition
EP0522091B1 (en) Use of a mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis
EP0650498B1 (en) Suppression of t-cell proliferation using peptide fragments of myelin basic protein
CA2203629A1 (en) Compositions and treatment for multiple sclerosis
JP6347065B2 (ja) ペプチド
JP2024520952A (ja) 免疫原性ペプチドを使用した改善された処置方法
ES2370957T3 (es) Composiciones que comprenden péptidos de la proteína básica de la mielina y sus utilizaciones médicas.
HK1142803B (en) Compositions comprising myelin basic protein peptides and medical uses thereof
Kela-Madar et al. Autoimmune spread to myelin is associated with experimental autoimmune encephalomyelitis induced by a neuronal protein, β-Synuclein

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130821

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250324

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250324

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250324

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251020

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251020

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251128